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medical device, whilst crucial for late-stage reimbursement decisions, is often ne-
glected by developers early on due to lack of data. The headroom method has been
proposed as a way to integrate economic evaluation into early go/no-go decisions.
By estimating the maximum reimbursable price (MRP) for a new device idea and
comparing this with forecasted developer’s costs, R&D resources can be chan-
nelled toward innovations for which future returns appear feasible. The aim of this
study was to evaluate the method by applying it retrospectively to a large and
diverse set of case studies, and comparing predicted ‘headroom’ with actual mar-
ket success, within the UK setting. METHODS: The method was applied systemat-
ically to twenty devices/diagnostics invented in the past, retrieved from the UK
national horizon scanning centre (NHSC)’s 2000-2009 database; literature searches
were date restricted to mimic the information available at the ‘concept stage’ of
development. Each case study was followed up to observe the product’s actual
market success or failure compared with the estimated ‘headroom’ and the devel-
opment decision this would have engendered, in order to explore the method’s
predictive value. RESULTS: Headroom correlated with subsequent market success
in 85% of cases. Headroom is most easily elicited where the change proposition of
the innovation is straightforward (e.g. direct replacement technologies); diagnostic
equipment posed particular difficulties. When the numerical headroom assess-
ments were considered alongside unquantifiable factors identified relating to the
clinical and market context, the method offered a good indication of future market
potential. CONCLUSIONS: Despite the strong advocacy of early economic evalua-
tion, the literature lacks a critical appraisal of any such method. This study for the
first time explores the potential implications of basing development decisions on
the headroom method, thereby assessing its potential value to stakeholders.
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Nurse-led self-help treatments for people with chronic fatigue syndrome/myalgic
encephalitis (CFS/ME) have been shown to be effective in reducing fatigue but their
cost-effectiveness is unknown. OBJECTIVES: To determine the cost-effectiveness
of alternative treatment options for people with CFS/ME in a primary care setting.
Design and setting Cost-effectiveness analysis conducted alongside a single blind
randomised controlled trial comparing pragmatic rehabilitation (PR) and support-
ive listening (SL) delivered by primary care nurses, and treatment as usual (TAU)
delivered by the general practitioner (GP) in North West England. METHODS: A
total of 296 patients aged 18 and over with CFS/ME diagnosed using the Oxford
criteria. A within trial analysis was conducted comparing the costs and quality
adjusted life years (QALYs) measured within the time frame of the trial. RESULTS:
Treatment as usual is less expensive and leads to better patient outcomes com-
pared with Supportive Listening. Treatment as usual is also less expensive than
Pragmatic Rehabilitation. PR was effective at reducing fatigue in the short term, but
the impact of the intervention on QALYs was uncertain. However, based on the
results of this trial, PR is unlikely to be cost-effective in this patient population.
CONCLUSIONS: This analysis does not support the introduction of SL. Any benefits
generated by PR are unlikely to be of sufficient magnitude to warrant recommend-
ing PR for this patient group on cost-effectiveness grounds alone. However, dissat-
isfaction with current treatment options means simply continuing with ‘treatment
as usual’ in primary care is unlikely to be acceptable to patients and practitioners.
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OBJECTIVES: To review published methods for estimating expected lifetime costs
in presence of censoring, to compare results with different methods and offer
suggestions for use in future research. METHODS: We searched the literature for
published methods for analysing cost data in presence of censoring. Methods were
assessed and compared with Monte-Carlo simulation using a hypothetical dataset,
introducing various degrees of censoring. All calculations were performed in
STATA 11.2. RESULTS: Different methods have been proposed to estimate lifetime
costs in presence of censoring. In the most commonly used methods, time is di-
vided into periods, the mean cost is estimated for each period and expected costs
estimated as a weighted sum across periods. However, the task of determining the
period length is normally left to the analyst. If time periods are too long informa-
tion risks being lost, while very short but frequent periods impedes calculation
speed. An alternative approach is proposed, which avoids the arbitrary choice of
period length. CONCLUSIONS: Expected lifetime costs can be estimated through a
weighted sum of all observed costs, with weights constructed by the Kaplan-Meier
survival probability and the number of patients at risk at the time each cost was
incurred. This avoids constructing time periods with arbitrary length and poten-
tially improves calculation speed or accuracy.
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OBJECTIVES:Thereexistsvery little inthewayofcurrentguidelinesor literatureastothe
combination and sequence of visualisation technologies (invasive or non-invasive) that
should be used for the visualisation of seizure focus in patients with refractory epilepsy
being considered for surgery. This lack of guidelines is typical in many diagnostic technol-
ogies. This study seeks to both create an explanatory analytical framework to demon-
strate the variety of technologies, sequences and combinations available before epilepsy
surgery is conducted, as well as focussing on the more general questions of the difficulties
associated with the evaluation of diagnostic technologies and consider the role of meth-
ods to characterise uncertainty in economic evaluations. METHODS: The decision an-
alytical framework consisted of three different potential strategies that could be
employed in order to elicit the most accurate information given an appropriate
cost-effectiveness threshold. This framework was used to consider the wider dif-
ficulties and sensitivities of the analysis of diagnostic technologies in combination.
RESULTS: The analytical framework section of this study found that (assuming an
initial MRI and video-EEG) a strategy of FDG-PET being the first test being per-
formed, followed by invasive EEG if the result of the test does not lead to a clear
decision on whether the patient should proceed to surgery was optimal.
CONCLUSIONS: In a general context, we found that in the evaluation of combina-
tions of diagnostic technologies it is important not only to consider the added value
of each individual test but also the correct combination and order in which the tests
are employed. In addition the evaluation of diagnostics will always be highly sen-
sitive to the cost-effectiveness of the subsequent treatment.
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OBJECTIVES: There is limited information associating CHA2DS2VASc and ATRIA scores
among patients newly prescribed an anticoagulant and stroke/systemic embolism (Sys-
Emb) and bleeding event rates in the real-world.METHODS:A retrospective analysis of
a de-identified, pharmacy-medical claims database was conducted in patients with
atrial fibrillation (AFIB) and new to dabigatran or warfarin (no drug 6-months prior)
from 1/1/10-2/28/11. Patients had continuous eligibility of 12 months prior to and 4
months post initial anticoagulation claim date. Patients’ CHA2DS2VASc, and
ATRIA risk scores were determined using demographic data and ICD-9/CPT codes
(2 separate dates) in the prior 12 months. Stroke/SysEmb risk was classified by
CHA2DS2VASc score as: low-risk0-1, moderate-risk2, and high-risk 2. Bleed-
ing risk using ATRIA score was classified as: low-risk0-3, moderate-risk4, and
high-risk 5. Stroke/SysEmb and bleeding events rates/100 patient years were
based on ICD-9 codes in the 4 months post anticoagulant initiation. RESULTS: A
total of 8,162 patients (warfarin7,072 and dabigatran1,090) were analyzed:
age7511 years (82%65 years); 57% were male; with a CHA2DS2VASc and ATRIA
risk scores of 3.81.7 and 2.81.9, respectively. At 4 months, Stroke/SysEmb and
overall bleeding event rates were 5.9% (95%CI 5.4% - 6.4%) and 11.1% (95%CI 10.4%
- 11.8%) respectively. As CHA2DS2VASc or ATRIA scores increased, so did the rates
for Stroke/SysEmb or bleeding events: Stroke/SysEmb low-risk: 0.88% (95%CI 0.18%
- 1.58%), moderate-risk: 1.76% (95%CI 0.95% - 2.57%) and high-risk: 7.05% (95%CI
6.43% - 7.67%); bleeding by ATRIA, low-risk: 8.62% (95%CI 7.93% - 9.31%), moderate-
risk: 16.79% (95%CI 14.15% - 19.43%) and high-risk: 21.69% (95%CI 19.21% - 24.17%).
CONCLUSIONS: Increasing CHA2DS2VASc and ATRIA scores were associated with
greater rates of Stroke/SysEmb or bleeding events in this real-world, anticoagulant-
treated population. Using claims-based CHA2DS2VASc and ATRIA scoring as a
screening tool may identify patients at risk of thromboembolic and bleeding events
when initiating anticoagulation therapy.
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OBJECTIVES: Real-world data sources (RWD) provide an important means for as-
sessing the real clinical outcomes and value of newly marketed drugs. We aimed to
develop a methodology to ascertain the feasibility of RWD in Europe to evaluate the
effectiveness of new anti-diabetic drugs. METHODS: We searched a proprietary
database of European RWDs and publicly available RWD initiatives (including
TRANSFoRm and ISPOR international digest of databases). Additional RWDs were
identified by literature search with PubMed and Google. A scoring algorithm was
developed to prioritize RWDs on the basis of availability of relevant attributes. Each
of 11 attributes was scored on a scale depending on the data to be captured and
weighted based on the attribute’s importance. According to our scoring algorithm,
a database could achieve a maximum of 70 points and a minimum of 50 points to
be sufficient for evaluating effectiveness. RESULTS: We identified 42 RWDs with
the potential for evaluating the effectiveness of anti-diabetic drugs and selected 25
for scoring after obtaining additional information. The scoring algorithm allowed
us to prioritise RWDs based on 3 key attributes: 1) number of patients prescribed
the drugs; 2) completeness of data for key parameters for which effectiveness was
to be evaluated (e.g. lab and biometric values); 3) non-parameter attributes (country
scope, ability to link to other RWDs, access and cost ). The algorithm yielded 16
RWDs meeting the predefined threshold of 50 points for evaluating effectiveness.
However, further assessment indicated low feasibility of the 16 RWDs without
linkage. CONCLUSIONS: We developed a unique and systematic approach to eval-
uating European RWDs; however, the main limitation of our methodology was the
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